Clearside Biomedical
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$2.15M
-0.1
-7.09
$306K
32
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Recently from Cashu
Please provide the content you'd like me to summarize regarding Clearside Biomedical, and I'll help you with a title.
Sure! Please provide the content you would like me to summarize, and I'll create an article based on it.
Please provide the content you would like summarized, and I'll create a title for you!
Sure! Please provide the text you would like me to summarize, and I'll be happy to help.
Clearside Biomedical's XIPERE Shows Promising Clinical Results in Ocular Therapy Advancement
Clearside Biomedical Advances Ocular Therapy with New Clinical Data Clearside Biomedical, a pioneering biotechnology firm specializing in treatments for eye diseases, announces promising results from…
Clearside Biomedical Innovates Ocular Drug Delivery with Suprachoroidal Injection Technology
Clearside Biomedical Advances in Ocular Drug Delivery Technology Clearside Biomedical is making significant strides in the field of ocular therapeutics with its innovative drug delivery platform desig…